Currently, 17 recruiting phase 1/2 clinical trials are being conducted, testing the possibility, effectiveness and safety of using anti-CD33, -CD123, -FLT3 or -CLL-1 CAR-T cells in AML therapy. Here, CLEC12A is linked to acute myeloid leukemia.